Jessica Jensen's most recent trade in Cardlytics Inc was a trade of 28,547 Restricted Stock Unit done . Disclosure was reported to the exchange on May 23, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cardlytics Inc | Jessica Jensen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2024 | 28,547 | 0 | - | - | Restricted Stock Unit | |
| Cardlytics Inc | Jessica Jensen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2024 | 28,547 | 38,606 (0%) | 0% | 0 | Common Stock | |
| POINT Biopharma Global Inc | D. Jessica Jensen | EVP Clinical Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 461,250 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | D. Jensen Jessica | EVP Clinical Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 213,301 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Jensen Jessica D. | EVP Clinical Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 136,055 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Jessica Jensen D. | EVP Clinical Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 125,553 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | D. Jensen Jessica | EVP Clinical Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 13,766 | 0 | - | - | Stock Option (Right to Buy) | |
| Cardlytics Inc | Jessica Jensen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 28,547 | 28,547 | - | - | Restricted Stock Units | |
| Cardlytics Inc | Jessica Jensen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2023 | 6,465 | 0 | - | - | Restricted Stock Units | |
| Cardlytics Inc | Jessica Jensen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2023 | 6,465 | 10,059 (0%) | 0% | - | Common Stock | |
| POINT Biopharma Global Inc | Jessica D. Jensen | EVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2023 | 136,055 | 136,055 | - | - | Stock Option (Right to Buy) | |
| Cardlytics Inc | Jessica Jensen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 6,465 | 6,465 | - | - | Restricted Stock Units | |
| Cardlytics Inc | Jessica Jensen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2022 | 1,701 | 3,594 (0%) | 0% | 0 | Common Stock | |
| Cardlytics Inc | Jessica Jensen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2022 | 1,701 | 0 | - | - | Restricted Stock Units | |
| POINT Biopharma Global Inc | Jessica D. Jensen | EVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 13,766 | 13,766 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Jessica D. Jensen | EVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 213,301 | 213,301 | - | - | Stock Option (Right to Buy) | |
| Cardlytics Inc | Jessica Jensen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2021 | 1,893 | 0 | - | - | Restricted Stock Units | |
| Cardlytics Inc | Jessica Jensen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2021 | 1,893 | 1,893 (0%) | 0% | - | Common Stock | |
| POINT Biopharma Global Inc | Jessica D. Jensen | EVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2021 | 461,250 | 461,250 | - | - | Stock Option (Right to Buy) | |
| Cardlytics Inc | Jessica Jensen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 1,701 | 1,701 | - | - | Restricted Stock Units | |
| Cardlytics Inc | Jessica Jensen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2020 | 1,893 | 1,893 | - | - | Restricted Stock Units |